Vermillion this week announced it had performed an estimated 2,935 OVA1 ovarian cancer tests during the fourth quarter ended Dec. 31, 2010 and an estimated 6,155 tests in all of 2010.

The fourth-quarter sales number represented a 48.8 percent increase over the third quarter of 2010, the company said in a statement, and the full-year 2010 figure of 6,155 exceeded the company's adjusted 2010 guidance of 5,000 to 5,500 tests, although it fell short of its initial 8,000 to 10,000 test guidance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.